11:47 AM EST, 12/11/2025 (MT Newswires) -- Illumina ( ILMN ) has entered into a collaboration and investment agreement with MyOme, a genomics and risk-modeling company, to help accelerate its proactive health initiatives, the companies said Thursday.

Financial details weren't disclosed.

The investment is designed to support MyOme's large-scale Proactive Health Trial, which seeks to prove that combining whole-genome sequencing, or WGS, with MyOme's proprietary AI-integrated risk models can enhance patient outcomes and deliver cost savings across chronic conditions, cancers, and rare diseases.

By combining Illumina's ( ILMN ) large-scale population health expertise with MyOme's risk-modeling technology, the companies aim to provide more accurate, ancestry-relevant disease-risk assessments to help patients better understand their chances of developing major health conditions

Price: 135.11, Change: +0.19, Percent Change: +0.14